UK MHRA Prohibited Ingredients List: Hidden Dangers for Importers
13. Mai 2026
UK MHRA Prohibited Ingredients: What Every Importer Must Know Before Customs Stops Your Shipment
UK MHRA prohibited ingredients claimed another wave of casualties in early 2026, when the agency's partnership with eBay resulted in 215 unauthorized product listings removed in a single enforcement sweep — a number that represents only the visible surface of a far deeper compliance crisis facing importers. Statutory Instrument 2024/1334 added 64 new CMR substances to the banned cosmetics list effective January 31, 2025, and many businesses are still scrambling to catch up. The rules are not simply stricter versions of EU or US frameworks. Post-Brexit, the UK has developed its own regulatory logic — one that treats certain substances as absolute prohibitions while applying concentration-based restrictions to others, in patterns that do not mirror either the EU Cosmetics Regulation or FDA guidelines. Importers who assume compliance with one jurisdiction guarantees compliance with another are routinely wrong. This guide maps the highest-risk ingredients, the most common formulation errors, and the documentation strategy that gives your shipments the best chance of clearing customs without delays or seizures.How the UK MHRA Prohibited Ingredients Framework Actually Works
The MHRA operates a dual-classification system that separates absolute prohibitions from restricted-use parameters. Absolute prohibitions apply zero tolerance regardless of concentration, intended use, or market precedent elsewhere. Restricted-use parameters permit defined concentrations under specific conditions, but those conditions are precise and not subject to interpretation at the point of import. The framework covers three overlapping regulatory categories: cosmetic ingredients governed by the UK Cosmetics Regulation, herbal medicinal components regulated under the Human Medicines Regulations 2012, and food contact substances under FSA jurisdiction. Importers frequently treat these as a single list. They are not. A substance may be prohibited in one category and restricted — but not banned — in another, creating enforcement asymmetries that catch even experienced compliance teams off guard. The MHRA's classification methodology prioritises genotoxic risk, particularly for products with sustained consumer exposure. An ingredient considered acceptable for rinse-off formulations may face prohibition in leave-on products targeting children or other vulnerable populations. The agency's science-based approach means the prohibited list is not static — it responds to emerging toxicology data, and the 2025 CMR expansion demonstrated how rapidly that list can grow.The 64 New CMR Substances: What SI 2024/1334 Changed
High-Risk Ingredients That Trigger Immediate MHRA Enforcement
Aristolochia Species
Aristolochia extracts carry the most severe enforcement response in the MHRA's herbal medicines prohibited list. Aristolochic acids are both nephrotoxic and carcinogenic, and the MHRA maintains zero tolerance for any detectable presence — regardless of concentration, dilution, or intended use claim. Shipments containing Aristolochia face immediate seizure. The contamination risk extends beyond intentional use. Aristolochia species grow alongside Clematis and Akebia in traditional Chinese medicine cultivation areas, creating substitution and co-harvesting risks. Importers sourcing TCM ingredients must require species-specific botanical authentication, not just genus-level identification.Mineral Oil Aromatic Hydrocarbons (MOAH) and MOSH
MOAH and MOSH moved to active enforcement priority following FSA alert FSA-FAFA-02-2025, which identified genotoxic carcinogen risks — specifically in products consumed regularly over sustained periods by children. While the alert was triggered by a food product (Jolly Rancher sweets), the enforcement implications extend to cosmetics containing petroleum-derived bases, particularly lip products accessible to young children. Plant-derived alternatives — squalane sourced from olives or sugarcane, caprylic/capric triglycerides, and fractionated coconut oil — eliminate MOAH/MOSH contamination risk while delivering equivalent emollient performance. Reformulating to these alternatives is not merely a compliance strategy; it is increasingly a market expectation among UK retailers conducting their own restricted substance audits.Kava-Kava (Piper methysticum)
Kava-kava extracts trigger enforcement action due to hepatotoxicity concerns documented across multiple post-market surveillance datasets. The MHRA requires comprehensive safety dossiers for any formulation containing kavalactones, and that requirement is rarely satisfied by standard supplier documentation. Products marketed with stress-relief or relaxation claims face the additional burden of potential medicinal classification, which elevates the compliance threshold further.Senecio Species and Pyrrolizidine Alkaloids
Senecio species alkaloids trigger automatic detention due to pyrrolizidine alkaloid (PA) content. The MHRA's analytical capabilities detect PAs at sub-parts-per-million levels, making inadequate cleaning validation between botanical processing runs a critical enforcement trigger. Cross-contamination during harvesting or processing can render entire product batches non-compliant, even when the Senecio species was never an intentional ingredient. PA risk extends beyond Senecio to Echinacea preparations, which must demonstrate absence of PA contamination despite INCI listings that reference only Echinacea purpurea extract. The MHRA holds importers responsible for complete chemical characterisation regardless of what supplier declarations state.Where UK Rules Diverge From EU and US Standards
The compliance gap between UK, EU, and US frameworks creates specific traps for importers operating across multiple markets. understanding cosmetic ingredient safety differences by market is now a non-negotiable competency for any serious import operation. Hydroquinone illustrates the divergence clearly. US over-the-counter regulations permit 2% concentration; EU markets allow prescription access; the UK maintains absolute prohibition due to depigmentation and nephrotoxicity concerns. A formulation compliant for export to both the US and EU will fail UK border inspection. Retinoic acid derivatives create a similar compliance asymmetry. The FDA permits tretinoin in prescription formulations, and EU cosmetic regulations allow retinyl palmitate at specified concentrations. The UK classifies these compounds as prescription-only medicines requiring MHRA licensing — meaning cosmetic products containing them are not merely restricted but in the wrong regulatory category entirely. Comfrey (Symphytum officinale) illustrates how UK MHRA prohibited ingredients policy differs from both the US and EU on botanicals. US dietary supplement rules permit comfrey with labeling restrictions. EU regulations allow external-use formulations. The UK's blanket prohibition on pyrrolizidine alkaloid-containing plants eliminates both approaches, leaving no pathway for compliant comfrey products in any format. Nanoparticle formulations face stricter treatment in the UK, particularly titanium dioxide and zinc oxide nanoparticles in leave-on products. The UK cites inhalation risk concerns not uniformly recognised by other jurisdictions, and INCI listings without specific nanoparticle and surface treatment declarations create enforcement ambiguity that triggers delays.
Formulation Errors That Generate Enforcement Actions
Concentration miscalculation in restricted ingredients generates consistent enforcement failures. The 1% kojic acid restriction requires analytical verification — not formulation intent. Raw material variability and blending inconsistencies routinely push finished products above permitted levels, particularly when importers rely on supplier-declared concentrations without independent testing. Stability testing gaps reveal prohibited degradation products absent from initial formulations. Certain UV filters and preservative systems generate carcinogenic breakdown products during normal shelf life, creating post-market compliance failures that escape pre-launch assessment. A product that passes initial testing may fail a market surveillance sample taken six months later. Combination product misclassification occurs when herbal formulations making health claims cross from cosmetic into medicinal territory. Any product containing herbal ingredients accompanied by therapeutic claims automatically requires THR (Traditional Herbal Registration) or a full product licence under Human Medicines Regulations 2012 — regardless of cosmetic ingredient compliance. The Business Companion guidance is explicit: MHRA classifies products by function and claim, not by ingredient list alone. Fragrance and flavour complex declarations create hidden compliance risks when umbrella INCI terms mask individual prohibited components. The MHRA requires disaggregated ingredient assessment for enforcement purposes, meaning prohibited allergens or sensitising substances buried within fragrance complexes will surface during analytical review even when the declaration appears complete.Building an Import Documentation Strategy That Holds Up to MHRA Scrutiny
Certificate of Analysis requirements for UK MHRA prohibited ingredients compliance extend beyond basic identity and purity testing. Botanical ingredients require pyrrolizidine alkaloid screening, heavy metals analysis, and microbiological verification, with analytical methods validated to ICH guidelines and detection limits set below regulatory concern thresholds. A standard CoA from a non-EU supplier rarely meets this specification without explicit contractual requirements. Product Information Files for cosmetic products must include safety assessments conducted by a qualified assessor with demonstrable familiarity with UK-specific requirements. EU CPSR protocols do not automatically satisfy UK PIF requirements post-Brexit, and assessors operating to EU frameworks without UK-specific updates create documentation that will not withstand MHRA scrutiny. Supplier qualification must go beyond paper audits. The MHRA's enforcement approach holds importers responsible for supplier performance, requiring audit trails, raw material sourcing controls, cross-contamination prevention records, and corrective action protocols. Importers who rely solely on supplier self-declarations are not meeting this standard. Customs documentation requires CAS numbers and concentration ranges for all ingredients. Generic descriptions or trade names create border delays when customs officers cannot verify prohibited ingredient absence. proper import compliance documentation for health and beauty products is the difference between routine clearance and a detained shipment.UK-Compliant Alternatives to the Most Commonly Prohibited Ingredients
Skin-brightening reformulations replacing kojic acid have strong options. Alpha-arbutin delivers comparable tyrosinase inhibition at 2–7% concentrations with a well-established safety profile. Licorice root extract (Glycyrrhiza glabra) and niacinamide at 5–10% provide multi-mechanism depigmentation activity without the sensitisation concerns that drove kojic acid restrictions. Herbal sedative applications can replace kava-kava with passionflower (Passiflora incarnata), lemon balm (Melissa officinalis), or chamomile (Matricaria chamomilla). Clinical data supports comparable efficacy for mild anxiety management, and none of these alternatives carry hepatotoxicity signals or trigger MHRA medicinal classification at standard use levels. Anti-inflammatory applications dependent on Senecio species have robust alternatives in turmeric extract (Curcuma longa), green tea polyphenols (Camellia sinensis), and willow bark extract (Salix alba). All three offer documented anti-inflammatory mechanisms, extensive safety records in cosmetic applications, and zero pyrrolizidine alkaloid risk. Preservative systems avoiding formaldehyde-releasing agents and restricted antimicrobials converge on synergistic combinations: phenoxyethanol paired with ethylhexylglycerin and caprylyl glycol provides broad-spectrum antimicrobial protection within UK safety parameters and performs well in sensitive skin formulations. This approach also satisfies clean beauty formulation standards increasingly demanded by UK retail buyers alongside regulatory compliance.
References
- UK Government. Banned and Restricted Herbal Ingredients for Medicinal Use. MHRA, 2024.
- MHRA. MHRA and eBay Working in Partnership to Safeguard Public Health. GOV.UK, April 2026.
- Food Standards Agency. Food Alert FSA-FAFA-02-2025: Mineral Oil Hydrocarbons. FSA, 2025.
- Nortier JL, et al. Urothelial Carcinoma Associated with the Use of a Chinese Herb (Aristolochia fangchi). New England Journal of Medicine. 2000;342(23):1686–1692.
- Teschke R, et al. Kava Hepatotoxicity: Pathogenetic Aspects and Prospective Considerations. Liver International. 2008;28(5):595–601.
- Wiedenfeld H. Plants Containing Pyrrolizidine Alkaloids: Toxicity and Problems. Food Additives and Contaminants: Part A. 2011;28(3):282–292.
- EUVerify. UK Cosmetics Banned and Restricted Ingredients — SI 2024/1334 Analysis. 2025.
